External validation of a digital pathology-based multimodal artificial intelligence (MMAI)-derived prognostic biomarker in the randomised phase III CHHiP trial. A phase 2 trial of darolutamide to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results